Q3 2025 Bristol-Myers Squibb Co Earnings Call Transcript
Key Points
- Bristol-Myers Squibb Co (BMY) reported a strong third quarter with a 17% year-over-year increase in sales from its Growth Portfolio, driven by multiple products including the IO portfolio, Reblozyl, Camzyos, and Breyanzi.
- The company raised its top-line guidance due to strong performance and maintained the midpoint of its bottom-line guidance.
- Recent product launches, Cobenfy and Qvantig, are performing well, with Cobenfy receiving positive feedback from physicians.
- Bristol-Myers Squibb Co (BMY) achieved several clinical and regulatory milestones, including a Breakthrough Therapy Designation for iza-bren and a Fast Track Designation for an anti-tau antibody for Alzheimer's disease.
- The company is actively pursuing business development opportunities, including the acquisition of Orbital Therapeutics to strengthen its cell therapy franchise.
- Despite strong sales growth, the company faces challenges in the entrenched market for Cobenfy, requiring ongoing efforts to increase prescribing breadth and depth.
- There is heightened investor nervousness around the ADEPT-2 study for Cobenfy, with concerns about potential site irregularities and data readout timelines.
- The company is navigating a dynamic policy environment, including potential impacts from the Inflation Reduction Act and other regulatory changes.
- Bristol-Myers Squibb Co (BMY) continues to face competition in the PD-1/PD-L1 space, requiring strategic positioning and rapid development to maintain market share.
- The company is managing cost pressures while balancing investments in its pipeline and growth portfolio, which could impact future financial flexibility.
Welcome to the Bristol-Myers Squibb third quarter 2025 earnings conference call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead.
Thank you, and good morning, everyone. We appreciate you joining our third quarter 2025 earnings call. With me this morning with prepared remarks are Chris Boerner, our Board Chair and Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call is Adam Lenkowsky, our Chief Commercialization Officer. And we welcome Cristian Massacesi, our recently appointed Chief Medical Officer and Head of Global Drug Development.
Earlier this morning, we posted our quarterly slide presentation to bms.com that you can use to follow along with Chris and David's remarks. Before we get started, I'll remind everybody that during this call, we will make statements about the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
